Quantcast

Latest Cancer immunotherapy Stories

2014-05-15 23:00:47

Created by Society for Immunotherapy of Cancer, this video was created to raise awareness about the excitement and the hope cancer immunotherapy clinical trials can offer patients with NSCLC today. Milwaukee, WI (PRWEB) May 15, 2014 A recently released video on cancer immunotherapy is offering new hope to patients with non-small cell lung cancer (NSCLC), the type of cancer which makes up 85% to 90% of all lung cancer cases in the US and claims more lives each year than colon, breast, and...

2014-05-12 08:30:31

BLUE BELL, Pa., May 12, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today reported financial results for the quarter ended March 31, 2014. Total revenue was $2.4 million for the three months ended March 31, 2014, compared to $1.5 million for the same period in 2013. Total operating expenses were $12.4 million compared to $8.1 million. The loss from operations prior to other income (expenses) for the quarter ended March 31, 2014, was $10.0 million, or $0.05...

2014-05-08 12:29:37

Tumors shrank or disappeared in some patients with advanced neuroblastoma in a Phase I study of an immune therapy manufactured at St. Jude Children's Research Hospital MEMPHIS, Tenn., May 8, 2014 /PRNewswire-USNewswire/ -- Tumors shrank or disappeared and disease progression was temporarily halted in 15 children with advanced neuroblastoma enrolled in a safety study of an experimental antibody produced at St. Jude Children's Research Hospital. Four patients are still alive after more...

2014-04-28 08:31:49

-Proceeds to Support Advancement of Clinical Programs in Cancer Immunotherapy - SANTA MONICA, Calif., April 28, 2014 /PRNewswire/ -- Kite Pharma, Inc. (Kite), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced the completion of a $50 million mezzanine private financing of convertible notes. Participants in the transaction included a syndicate of healthcare-dedicated...

2014-04-25 23:05:21

According to a new report from BCC Research the global market for cancer immunotherapies is expected to grow to nearly $67.9 billion by 2018, with a five-year compound annual growth rate (CAGR) of 14.7%. North American market, the fastest growing regional segment overall, is growing at a tremendous 15% CAGR. Wellesley, Mass. (PRWEB) April 25, 2014 BCC Research (http://www.bccresearch.com) reveals in its new report, CANCER IMMUNOLOGY AND ONCOLYTIC VIROLOGY: TECHNOLOGIES AND GLOBAL MARKETS,...

2014-04-24 08:33:57

Leading Cancer Immunotherapy Startup also Bolsters Leadership Team with Two Key Appointments SEATTLE, April 24, 2014 /PRNewswire-USNewswire/ -- Juno Therapeutics, a biotechnology company focused on bringing forward novel immunotherapies for cancer, today announced the close of its Series A round with $176M in fully committed funds. http://photos.prnewswire.com/prnvar/20140113/DC45426LOGO Juno's initial funding of $120 million came predominantly from leading technology venture...

2014-04-07 16:25:44

Largest-ever gift to the Hutch promises to save lives by broadening the application of immunotherapy to lung, ovarian, pancreatic and colon cancers SEATTLE, April 7, 2014 /PRNewswire/ -- Fred Hutchinson Cancer Research Center scientists striving for new cancer cures -- and the patients who stand to benefit from them -- got an enormous boost today when the Bezos family committed $20 million to support the development of novel cancer immunotherapies. It is the largest single...

2014-04-03 08:29:54

Novel methodology leverages somatic hypermutation to rapidly generate humanized therapeutic antibodies with >97% human content SAN DIEGO, April 3, 2014 /PRNewswire/ -- AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, announced today that the U.S. Patent and Trademark Office (USPTO) has issued US Patent #8,685,897 broadly covering a novel approach to antibody humanization using somatic hypermutation. Leveraging key advantages of AnaptysBio's...

2014-03-31 08:30:41

Morgan Stanley's Head of Global Biotech Investment Banking Joins Leading Cancer Immunotherapy Startup SEATTLE, March 31, 2014 /PRNewswire/ -- Juno Therapeutics, a biotechnology company focused on bringing forward novel immunotherapies for cancer, announced today that Steve Harr, M.D., will join the company as its Chief Financial Officer and Head of Corporate Development. http://photos.prnewswire.com/prnvar/20140113/DC45426LOGO Harr currently serves as Managing Director and Head of...

2014-03-31 08:29:19

SANTA MONICA, Calif., March 31, 2014 /PRNewswire/ -- Kite Pharma, Inc. (Kite), a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT(TM)) products for cancer, today announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development granted orphan drug designation for the Company's lead investigational therapy, an autologous engineered T cell product that targets CD19 expression on B cell malignancies, for...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.